Identification of prior dengue-naïve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines

Identification of prior dengue-naïve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines

IntroductionDengue virus (DENV) is the leading cause of mosquito-borne viral diseases in humans. Dengvaxia, the first licensed dengue vaccine, is recommended for DENV-seropositive individuals aged 9–45 years. In the Philippines, Dengvaxia was administered to more than 830,000 children without prior...

Full description

Bibliographic Details
Main Authors: Yu-Ching Dai, Ava Kristy Sy, Mario Jiz, Jih-Jin Tsai, Joan Bato, Mary Ann Quinoñes, Mary Anne Joy Reyes, Wei-Kung Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Immunology
Subjects:
dengue virus
vaccine
Dengvaxia
serostatus
enzyme-linked immunosorbent assay
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1202055/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1202055/full

Similar Items